

DAFTAR PUSTAKA

- Adelmann, T., Ioiart, I., Ceausu, R., Sarb, S. dan Suci, C., 2018. 'Immunohistochemical expression of vascular endothelial growth factor does not correlate with microvessel density in invasive bladder carcinoma'. *Research and Clinical*, hal.12.
- Al-Abbasi, D.S., As'ad, A., Al-Toriahi, K.M., Jabor, T.A. dan Yasseen, A.A. 2009. 'Expression of VEGF in urinary bladder transitional cell carcinoma in an Iraqi population subjected to depleted uranium: an immunohistochemical study'. *Applied Immunohistochemistry & Molecular Morphology*, 17(4), hal.307-311.
- Al-Bassam, S. S. A., H. S. Kadhim dan Khashman, B. M. 2014. 'Possible association of vascular endothelial growth factor with grades of breast cancer'. *Int. J. Res. Pharm. Chem.*, 4: hal.291-293.
- Ali, H. H., Ibraheem, M. H. dan Alhindawi, M. M. 2018. 'Immunohistochemical expression of matrix metalloproteinase-9 in urothelial carcinoma of urinary bladder'. *Kasr Al Ainy Medical Journal*, 24(3), hal.109.
- Amalinei, C., Caruntu, I. D. dan Balan, R.A. 2007. 'Biology of metalloproteinases'. *Rom J Morphol Embryol*, 48(4), pp.323-334.
- Amalinei, C., Caruntu, I. D., Giuşca, S. E. dan Balan, R. A. 2010. 'Matrix metalloproteinases involvement in pathologic conditions'. *Rom J Morphol Embryol*, 51(2), hal.215-228.
- Babjuk, M., Böhle, A., Burger, M., Compérat, E., Kaasinen, E., Palou, J., Rouprêt, M., Van Rhijn, B. W. G., Shariat, S. F., Sylvester, R., Zigeuner, R., Capoun, O., Cohen, D., Hernandez, V. dan Soukup, V. 2016. 'EAU Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS)'. *European Association of Urology*.
- Bauvois, B. 2012. 'New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression'. *Biochim Biophys Acta*;1825: hal.29-36).
- Behl, V., Harsh M., Chauhan N., dan Biswas M. 2017. 'Expression of VEGF in patients of urinary bladder carcinoma'. *J Evid Based Med. Healthc.* 4(56), hal.3393-339.
- Burger, M., Catto, J.W., Dalbagni, G., Grossman, H.B., Herr, H., Karakiewicz, P., Kassouf, W., Kiemeny, L.A., La Vecchia, C., Shariat, S. dan Lotan, Y. 2013. 'Epidemiology and risk factors of urothelial bladder cancer'. *European urology*, 63(2), hal.234-241.

- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R., Torre, L. dan Jemal, A. 2018. 'Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries', *Ca Cancer J Clin*, 68, hal. 394–424.
- Bronsert, P. dan Werner, M. 2018. '*Pathology of tumor angiogenesis*', Springer International Publishing AG, part of Springer Nature
- Brown, G. T. dan Murray, G. I. 2015. 'Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis'. *The Journal of pathology*, 237(3), hal.273-281.
- Cathcart, J., Pulkoski-Gross, A., dan Cao, J. 2015. 'Targeting matrix metalloproteinases in cancer: bringing new life to old ideas'. *Genes & diseases*, 2(1), hal.26-34.
- Chen, Q., Liu, L. Z., Li, C., Jing, Y., Carpenter, R., Jiang, Y., dan Jiang, B. H. 2011. 'MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1 α expression'. *PloS one*, 6(4), hal.119-139.
- Choi, C. H., Song, S. Y., Choi, J. J., Park, Y. A., Kang, H., Kim, T. J., Lee, J. W., Kim, B. G., Lee, J. H. dan Bae, D. S. 2008. 'Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy'. *BMC cancer*, 8(1), hal.295.
- Chow, N.H., Liu, H.S., Chan, S.H., Cheng, H.L. dan Tzai, T.S., 1999. 'Expression of vascular endothelial growth factor in primary superficial bladder cancer'. *Anticancer research*, 19(5C), hal.4593-4597.
- Comp erat, E. Varinot, J., Moroch, J., Eymerit-morin, C. dan Brimo, F. 2018. 'A practical guide to bladder cancer pathology', Nature Publishing Group. Nature Publishing Group, hal. 1–12..
- Conlon, G. A. dan Murray, G. I. 2019. 'Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis'. *The Journal of pathology*, 247(5), hal.629-640.
- Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D. 1997. 'Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer'. *Cancer Res*;57: hal.5281–5
- Cumberbatch, M. G. dan Noon, A. P. 2019. 'Epidemiology, aetiology and screening of bladder cancer'. *Translational andrology and urology*, 8(1), hal.5.
- DeGeorge, K. C., Holt, H. R. dan Hodges, S. C. 2017. 'Bladder cancer: Diagnosis and treatment', *American Academy of Family Physicians*, 96(8), hal. 507–514.

- Dobruch J., Daneshmand S., Fisch M., Yair L., Aidan P.N., Matthew J. R., Shahrokh F.S., Alexandre R. Z., Stephen A.B. 2016. 'Gender and bladder cancer: a collaborative review of Etiology, Biology, and Outcomes'. *Eur Urol*;69: hal.300-10.
- Donmez, G., Sullu, Y., Baris, S., Yildiz, L., Aydin, O., Karagoz, F. dan Kandemir, B., 2009. 'Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas'. *Pathology-Research and Practice*, 205(12), hal.854-857.
- Dufour, A., Sampson, N.S., Zucker, S. dan Cao, J. 2008. 'Role of the hemopexin domain of matrix metalloproteinases in cell migration'. *Journal of cellular physiology*, 217(3), hal.643-651.
- Durkan, GC., Nutt, JE., Marsh, C., Rajjayabun, PH., Robinson, MC., Neal, DE., Lunec, J. dan Mellon, K. 2003. 'Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer'. *Clin Cancer Res* 9: hal.2576–2582.
- Feng, C., Wu, Z., Guo, T., Jiang, H., Guan, M., Zhang, Y., Wen, H. dan Ding, Q., 2012. 'BLCA-4 expression is related to MMP-9, VEGF, IL-1 α and IL-8 in bladder cancer but not to PEDF, TNF- α or angiogenesis'. *Pathologie Biologie*, 60(3), hal. e36-e40.
- Ferrara, N. 2009. 'VEGF-A: a critical regulator of blood vessel growth'. *Eur Cytokine Netw* 20: hal.158–163.
- Gebala, V., Collins, R., Geudens, I., Phng, L. K., Gerhardt, H. 2016. 'Blood flow drives lumen formation by inverse membrane blebbing during angiogenesis in vivo'. *Nat Cell Biol* 18: hal.443–450.
- Garcia-Closas, M., Malats, N., Real, F.X., Yeager, M., Welch, R., Silverman, D., Kogevinas, M., Dosemeci, M., Figueroa, J., Chatterjee, N. dan Tardón, A. 2007. 'Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk'. *PLoS genetics*, 3(2), hal. 29.
- Ghoneim, M. A., Abdel-Latif, M., El-Mekresh, M., Abol-Enein, H., Mosbah, A., Ashamallah, A. dan El-Baz, M. A. 2008. 'Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later'. *The Journal of urology*, 180(1), hal.121-127.

- Grignon, D. J., Al-Ahmadie, H., Algaba, F., Amin, M. B., Comperat, E. M., Dyrskjot, L., Epstein, J. I., Hansel, D. E., Knuchel, R., Lioreta, J., Lopez-Beltran, A., McKenney, J. K., Netto, G. J., Paner, G., Reuter, V. E., Shen, S. S. dan Van der Kwast, T. 2015. 'Urothelial tumours infiltrating urothelial carcinoma', WHO Classification of tumours of the urinary system and male genital organ. 4th edn. *International Agency for Research on Cancer (IARC)*, hal. 81–105.
- Giridhar, K. V. dan Kohli, M. 2017. 'Management of muscle-invasive urothelial cancer and the emerging role of immunotherapy in advanced urothelial cancer'. In *Mayo Clinic Proceedings* 92(10), hal. 1564-1582. Elsevier.
- Grzególkowski, P., Kaczmarek, K., Lemiński, A., Soczawa, M., Gołąb, A. dan Słojewski, M. 2017. 'Assessment of the infiltrative character of bladder cancer at the time of transurethral resection : a single center study', *Central European Journal of Oncology*, 70, hal. 22–26.
- Gunes, M., Kemik, A. S., Pirincci, N., Gecit, I., Taken, K., Yuksel, M. B., Kaba, M. dan Eryilmaz, R. 2013. 'Preoperative levels of matrix metalloproteinase-7 and-9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients'. *Asian Pacific Journal of Cancer Prevention*, 14(2), hal.873-876.
- Hoeben, A.N.N., Landuyt, B., Highley, M.S., Wildiers, H., Van Oosterom, A.T. dan De Bruijn, E.A., 2004. 'Vascular endothelial growth factor and angiogenesis'. *Pharmacological reviews*, 56(4), hal.549-580.
- Hoffman, K.L., Lerner, S.P. dan Smith, C.L. 2013. 'Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation'. *Hormones and Cancer*, 4(1), hal.24-35
- Huang, H. 2018. '*Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances*'. *Sensors*, 18(10), hal.3249.
- Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M., Reuter, V. E. dan Catto, J. 2016. 'Guidelines the 2016 WHO classification of tumours of the urinary system and male genital organs — Part B : prostate and bladder tumours', *European Urology. European Association of Urology*, 70(1), hal. 106–119.
- Inamura, K. 2018. '*Bladder cancer: new insights into its molecular pathology*' *Cancers*, 10(4), hal.100.
- Kader, A.K., Liu, J., Shao, L., Dinney, C.P., Lin, J., Wang, Y., Gu, J., Grossman, H.B. dan Wu, X. 2007. 'Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness'. *Clinical cancer research*, 13(9), hal.2614-2620.

- Kaya, A., Çiledag, A., Gulbay, B.E., Poyraz, B.M., Çelik, G., Sen, E., Savas, H. dan Savas, I. 2004. 'The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients'. *Respiratory medicine*, 98(7); hal.632-636.
- Kementrian kesehatan Republik Indonesia. 2013. *Riset kesehatan dasar; RISKESDAS*. Jakarta: *Balitbang kemenkes RI*
- Kerbel, R.S., 2008. 'Tumor angiogenesis'. *New England Journal of Medicine*, 358(19); hal.2039-2049.
- Kim, H. S. Ku, J. H., Kim, S. J., Hong, S. J., Hong, S. H., Kim, H. S., Kwon, T. G., Cho, J. S., Jeon, S. S., Joo, K. J., Ahn, H. J., Park, H. S., Seong, D. H., Kwon, D. D., Kim, H. J., Sung, L. J. dan Hyung-Lae, L. 2016. 'Prognostic factors for recurrence and progression in Korean non-muscle-invasive bladder cancer patients : A retrospective , multi-institutional study', *Yonsei Med J*, 57(4); hal. 855–864.
- Koch, A. W., Mathivet, T., Larrivé, B., Tong, R. K., Kowalski, J., Pibouin-Fragner, L., Bouvrée, K., Stawicki, S., Nicholes, K., Rathore, N. dan Scales, S.J. 2011. 'Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B'. *Developmental cell*, 20(1); hal. 33-46.
- Kopparapu, P.K., Boorjian, S.A., Robinson, B.D., Downes, M., Gudas, L.J., Mongan, N.P. dan Persson, J.L., 2013. 'Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.' *Anticancer research*, 33(6); hal.2381-2390.
- Krabbe, L.M., Svatek, R.S., Shariat, S.F., Messing, E. dan Lotan, Y., 2015. 'Bladder cancer risk: use of the PLCO and NLST to identify a suitable screening cohort'. *Elsevier* 33(2), hal. 65-119.
- Lammert, E. dan Axnick, J. 2012 'Vascular lumen formation'. *Cold Spring Harb Perspect Med* 2: hal.619.
- Larrivee, B., Freitas, C., Trombe, M., Lv, X., DeLafarge, B., Yuan, L., Bouvrée, K., Bréant, C., Del Toro, R., Bréchet, N., dan Germain, S. 2007. 'Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis' *Genes & development*, 21(19); hal.2433-2447.
- Li, Z., Zhu, Y., Li, C., Trinh, R., Ren, X., Sun, F., Wang, Y., Shang, P., Wang, T., Wang, M. dan Morrison, S.L., 2017. 'Anti-VEGFR2-interferon- α 2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer'. *Oncoimmunology*, 6(3); hal.212-238.

- Lindner, D.J., 2002. 'Interferons as antiangiogenic agents'. *Current Oncology Reports*, 4(6), hal.510-514.
- Liu, D., Guo, H., Li, Y., Xu, X., Yang, K., Bai, Y. 2012. 'Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: A meta-analysis'. *PLoS One* 7: hal 231-251
- Magalhaes, A. dan Dias, S. 2019. *Angiogenesis—vessels recruitment by tumor cells*'. *Molecular and Cell Biology of Cancer*. Springer, Cham. hal. 141-157
- Magers, M. J., Lopez-Beltran, A., Montironi, R., Williamson, S. R., Kaimakliotis, H. Z., dan Cheng, L. 2019. 'Staging of bladder cancer'. *Histopathology*, 74(1), hal 112-134.
- Marcus, G. K., Jubber, I., Black, P. C., Esperto, F., Figueroa, J. D., Kamat, A. M., Kiemenev, L., Lotan, Y., Pang, K., Silverman, D. T. dan Znaor, A. 2018. 'Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018'. *European urology*.
- Moschini, M., Shariat, S. F., Abufaraj, M., Soria, F., Klatte, T., La Croce, G., Mattei, A., Damiano, R., Salonia, A., Montorsi, F. dan Briganti, A. 2017. 'The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes'. In *Urologic Oncology: Seminars and Original Investigations*. 35(4), hal. 151-217.
- Nagy, J. A., Dvorak, A. M., Dvorak, H. F. 2007. 'VEGF-A and the induction of pathological angiogenesis'. *Annu Rev Pathol* 2: hal.251–275.
- Nussenbaum, F., dan Herman, I. M. 2010. 'Tumor angiogenesis: insights and innovations'. *Journal of oncology*, 2010, hal.132-641.
- Özemir, E., Kakehi, Y., Okuno, H. dan Yoshida, O. 1999. 'Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas'. *Journal Urol* 161: hal. 1359–1363.
- Pornchai, O., Rhys-Evans, P. H. dan Eccles, S.A. 2001. 'Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck'. *Archives of Otolaryngology–Head & Neck Surgery*, 127(7), hal.813- 820.
- Ragab, H. M., Shaaban, H. M., Maksoud, N. A., Radwan, S. M., Elaziz, W. A., dan Hafez, N.H. 2016. 'Expression of vascular endothelial growth factor protein in both serum samples and excised tumor tissues of breast carcinoma patients'

- Reis, S.T., Leite, K.R.M., Piovesan, L.F., Pontes-Junior, J., Viana, N.I., Abe, D.K., Crippa, A., Moura, C.M., Adonias, S.P., Srougi, M. dan Dall'Oglio, M.F., 2012. 'Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of bladder cancer'. *BMC urology*, 12(1), hal.18.
- Roskoski, R. 2017. 'Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas'. *Pharmacol Res* 120: hal.116–132.
- Shen, S.S., Smith, C.L., Hsieh, J.T., Yu, J., Kim, I.Y., Jian, W., Sonpavde, G., Ayala, G.E., Younes, M. dan Lerner, S.P. 2006. 'Expression of estrogen receptors- α and- β in bladder cancer cell lines and human bladder tumor tissue'. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 106(12), hal.2610-2616.
- Shibuya, M., dan Claesson-Welsh, L. 2006. 'Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis'. *Exp Cell Res*;312: hal.549-60.
- Shibuya, M. 2011. 'Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies'. *Genes & cancer*, 2(12), hal.1097–1105.
- Shin, J. H., Lim, J. S. dan Jeon, B. H. 2018. 'Pathophysiology of bladder cancer, *Bladder Cancer*'. Elsevier Inc.
- Soukup, V. Capoun, O., Cohen, D., Hernandez, V., Babjuk, M., Burger, M., Comperat, E., Gontero, P., Lam, T., Maclennan, S., Mostafid, A. H., Palou, J., Van Rhijn, B. W.G., Roupret, M., Shariat, S. F., Sylvester, R., Yuan, Y. dan Zigeuner, R. 2017 'Prognostic Performance and Reproducibility of the 1973 and 2004 / 2016 World Health Organization Grading Classification Systems in Non – muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel', *European Urology*.
- Spill, F., Reynolds, D.S., Kamm, R.D. dan Zaman, M.H., 2016. 'Impact of the physical microenvironment on tumor progression and metastasis'. *Current opinion in biotechnology*, 40, hal.41-48.
- Sternlicht, M.D., Coussens, L.M., Vu, T.H. dan Werb, Z., 2001. 'Biology and regulation of the matrix metalloproteinases. In *Matrix metalloproteinase inhibitors in cancer therapy*' (hal. 1-37). Humana Press, Totowa, NJ.
- Tamura, R., Tanaka, T., Akasaki, Y., Murayama, Y., Yoshida, K. dan Sasaki, H., 2020. 'The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications'. *Medical Oncology*, 37(1), hal.2.
- Tanaka, M. F. dan Sonpavde, G. 2015. 'Diagnosis and management of urothelial carcinoma of the bladder diagnosis and management of urothelial carcinoma of the bladder', *Postgraduate Medicine*, 123(3), hal. 43–55.

- Tang, Z., Tang, C., Juanfen, M.O. dan Ying, X. 2018. 'Role of MMPs expression in the invasion and metastasis of bladder cancer'. *Chinese Journal of Primary Medicine and Pharmacy*, 25(2), hal.156-160.
- Tilki, D., Svatek, R. S., Novara, G., Seitz, M., Godoy, G., Karakiewicz, P. I., Kassouf, W., Fradet, Y., Fritsche, H. M., Sonpavde, G. dan Izawa, J. I. 2010. 'Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients'. *The Journal of urology*, 184(3), hal.888-894.
- Theodoropoulos, V.E., Lazaris, A.C., Sofras, F., Gerzelis, I., Tsoukala, V., Ghikonti, I., Manikas, K. dan Kastriotis, I. 2004. 'Hypoxia-inducible factor 1 α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer'. *European urology*, 46(2), hal.200-208.
- Umbas, R., Hardjowijoto, S., Mochtar, C. A., Safriadi, F., Djatisoesanto, W., Oka, A. A. G., Penta, K., Sihombing, A. T., Warli, S. M. dan Hendri, A. Z. 2014. 'Panduan penanganan kanker kandung kemih tipe urotelial' Jakarta: Ikatan Ahli Urologi Indonesia (IAUI).
- Vandooren, J., Van den Steen, P.E. dan Opdenakker, G. 2013. 'Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade'. *Critical reviews in biochemistry and molecular biology*, 48(3), hal.222-272.
- Vasala, K., Paakko, P. dan Turpeenniemi-Hujanen, T. 2008. 'Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis'. *Anticancer research*, 28(3B), hal.1757-1761.
- Wallard, M.J., Pennington, C.J., Veerakumarasivam, A., Burt, G., Mills, I.G., Warren, A., Leung, H.Y., Murphy, G., Edwards, D.R., Neal, D.E. dan Kelly, J.D. 2006. 'Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma'. *British journal of cancer*, 94(4), hal.569-577.
- Wieczorek, E., Jablonowski, Z., Tomasik, B., Konecki, T., Jablonska, E., Gromadzinska, J., Fendler, W., Sosnowski, M., Wasowicz, W. dan Reszka, E. 2015. 'MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer'. *Clinical biochemistry*, 48(18), hal.1235-1240.
- Witjes, J. A., Compérat, E., Cowan, N. C. De Santis, M., Gakis, G., Lebrét, T., Van Der Heijden, A. G., Ribal, M. J., Bruins, Hernández, V., Espinós, E. L., Dunn, J., Rouanne, M., Neuzillet, Y. dan Veskimäe, E. 2016. 'EAU Guidelines on and Metastatic Bladder Cancer'. *European Association of Urology*.
- Wojcik, E. M., dan Pambuccian, S. E. 2016. 'Pathogenesis of urothelial Carcinoma', *Springer International Publishing Switzerland*, hal. 8–11.

- Wu, W.Z., Sun, H.C., Shen, Y.F., Chen, J., Wang, L., Tang, Z.Y., Iliakis, G. dan Liu, K.D., 2005. 'Interferon alpha 2a downregulates VEGF expression through PI3 kinase and MAP kinase signaling pathways'. *Journal of cancer research and clinical oncology*, 131(3), hal.169-178.
- Wu, G.J., Bao, J.S., Yue, Z.J., Zeng, F.C., Cen, S., Tang, Z.Y. dan Kang, X.L. 2018. 'Elevated expression of matrix metalloproteinase-9 is associated with bladder cancer pathogenesis'. *Journal of cancer research and therapeutics*, 14(8), hal.54.
- Yang C.C., Chu K.C. dan Yeh W.M. 2004. 'The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression'. *Urol Oncol*. 22(1); hal.1-6.
- Yaseen, N.Y., Aziz, R.S., Saleem, M.A., Al-Azzawi, I.S. dan AL-biaty, H.S., 2016. 'Urinary marker (MMP-9) and bladder cancer'. *Iraqi Journal of Cancer and Medical Genetics*, 9(1), hal.5-18.
- Zhang, S., Li, L., Lin, J.Y. dan Lin, H., 2003. 'Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma'. *World Journal of Gastroenterology*, 9(5), hal.899.
- Zhao, M., He, X. L. dan Teng, X. D. 2016. 'Understanding the molecular pathogenesis and prognostics of bladder cancer : an overview', *Chinese Journal of Cancer Research*, 28(1), hal. 92–98.
- Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa Hl. 2006. 'Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma'. *Anticancer Res.*; 26: hal.3579-84.
- Zhu, F., Zhang, Y., Yan, R., Zhang, H. dan Zhang, Y. 2009. 'Correlation of expressions of MMP-2 and MMP-9 in the transitional cell carcinoma of bladder with tremor invasion and metastasis'. *Cancer Research and Clinic*, 21(10), hal.680-682.